Unleash the Power of Digital Pathology in the Era of Precision Medicine
DPA's Exhibitor Seminar at USCAP 2017

Monday, March 6, 2017
6:30-8:00 AM
San Antonio Grand Hyatt Hotel | Bowie Room 

This seminar will discuss contemporary topics, such as multimedia imaging in healthcare and its impact on pathologists and digital pathology vendors, and the potential role of PD-L1 automated image analysis algorithms in lieu of quantitative image analysis of biomarkers. It will also highlight the best practices of digital pathology in improving diagnostic accuracy, work flow and cost reduction to ensure better patient care in the era of precision medicine. 


  • Update the advances of digital pathology
  • Review multimedia imaging in healthcare and its impact on pathologists and digital pathology vendors
  • Highlight the best practices of digital pathology in improving diagnostic accuracy, work flow and cost reduction
  • Discuss the available resources and the potentials of incorporation of digital pathology into practice
  • Review the potential role of PD-L1 automated image analysis algorithms in lieu of quantitative image analysis of biomarker in drug development


The Best of Pathology Visions by Dr. Marilyn Bui
Pathology Visions is the annual scientific meeting of the Digital Pathology Association. This highlight of the best presentations at the most recent as well as past Pathology Visions conferences will focus on the best examples of incorporation of digital pathology into pathology practice to improve diagnostic accuracy and efficiency. Lessons learnt and future opportunities will also be discussed.

Historical and current state of digital pathology and WSI in pathology practice by Dr. Eric Glassy
Digital pathology continues to evolve as vendors arrive, exit, and form new alliances. Hardware platforms have matured but software continues to innovate, with a new focus on image analysis and workflow efficiency. This introductory section will review these changes and set the stage for further advances as pathology doubles down on a future based on pixels.

Automated Image Analysis of Immunohistochemistry as a Biomarker for Drug Development and Companion Diagnostics by Dr. Michael Montalto
Immune checkpoint modulators are rapidly changing the way cancer is treated. Biomarkers that can predict response to these class of drugs are becoming increasingly important in current pathology practice. Specifically, several PD-L1 immunohistochemistry (IHC) assays are approved by the FDA as companion and complimentary diagnostics for various immune checkpoint inhibitors. This presentation will review the state of PD-L1 IHC assay use for determining therapeutic eligibility, as well as the respective views from the diagnostic and pharmaceutical industry on complimentary/companion test development. The previously reported results of the NCCN/BMS Assay Comparison will also be highlighted. The potential role of PD-L1 automated image analysis algorithms to augment PD-L1 IHC testing in the clinic will be highlighted in the context of biomarker and companion test development for IHC markers.

Impact of Enterprise Imaging on Pathology by Dr. Liron Pantanowitz
Historically, pathologists managed images at a departmental level and were not concerned with providing users from outside the department with access to their images. Today, Enterprise (or multimedia) Imaging strategies at many institutions are beginning to embrace pathology images. There are different technical platforms, approaches, and practices for managing Enterprise Imaging data. These repositories are sometimes branded as vendor neutral archives. In the interest of interoperability, standards such as DICOM are being emphasized. Pathologists will soon be progressively pressurized to partake in these initiatives. Whole slide imaging vendors manufacturing proprietary systems will accordingly need to offer their clients more standard-compliant images and services. This talk addresses the emerging era of Enterprise Imaging in healthcare and its impact on pathologists and digital pathology vendors.


Marilyn M. Bui, MD, PhD
Dr. Bui is certified in Anatomic/Clinical Pathology and Cytopathology by American Board of Pathology. She is the Scientific Director of Analytic Microscopy Core at Moffitt Cancer Center (MCC) and the Director of Cytopathology Fellowship Program at the University of South Florida Morsani College of Medicine. Practicing as an academic pathologist at MCC, a premier cancer center in America and the only NCI/NIH designated comprehensive cancer center in Florida, she has published over 120 peer-reviewed articles, 8 book chapters and 1 book. She has earned national and institutional awards in cancer research and education. Dr. Bui has expertise in digital pathology (DP). Her prior publication and presentation addressed the clinical, teaching and image analysis utility of DP. She is an executive board member of Digital Pathology Association, a member of the College of American Pathologists Digital Pathology Committee and an editorial board member of Journal of Pathology Informatics.

Eric F. Glassy, MD, FCAP
Dr. Glassy is a community pathologist in Southern California. He shares time between Pathology Inc., a reference laboratory and Affiliated Pathologists Medical Group, a 38 man independent pathology corporation. Dr. Glassy has served as medical director for several laboratories and has won numerous pathology awards, including the Distinguished Service Award and Excellence in Education Award from the College of American Pathologists. He has chaired hospital as well as national committees for the CAP. He served as chairman of the Hematology and Clinical Microscopy Resource, Publications, Curriculum and Digital Pathology Committees of the CAP. He is a past Board Member of the CAP Foundation and a graduate of the Engaged Leadership Academy. He is president of the Digital Pathology Association. He edited, wrote and illustrated several pathology color atlases and developed software programs for pathology reporting, outreach, and practice management. He holds a green belt in Six Sigma.

Michael C. Montalto, PhD
Dr. Montalto is a research and development leader with a broad range of experience at the executive level including R&D, Regulatory, Clinical, Medical and Scientific Affairs. He is currently Executive Director and Head of Immunohistochemistry (IHC) and Pathology Biomarkers at Bristol-Myers Squibb, where he leads histopathology-based assay development for exploratory clinical biomarker and companion diagnostic efforts. Prior to this role, Dr. Montalto was a co-founder of Omnyx L.L.C., a joint venture of GE and University of Pittsburgh Medical Center that commercialized diagnostic pathology imaging and software products. He has patented and published on novel pathology-based multiplex technology (MultiOmyx™;Clarient) for oncology biomarker discovery. He has designed and led global clinical trials for in vitro diagnostic digital pathology devices and served as chair of the regulatory task force of the Digital Pathology Association. He has served as a member of NIH study sections for in vivo cellular imaging centers and currently serves as an officer and executive member of the Digital Pathology Associations (DPA) Board of Directors. Dr. Montalto earned is PhD in cell and molecular biology of cancer from Albany Medical College and received his post-doctoral training in anti-inflammatory drug discovery and whole animal physiology at Brigham and Womens Hospital, Harvard Medical School.

Liron Pantanowitz, MD
Dr. Pantanowitz is the Director of Cytopathology at UPMC Shadyside. He is also the Director of the Pathology Informatics Fellowship Program and the Director of the Pathology Informatics Division.

This Exhibitor Seminar is not a part of the official USCAP Educational Program at the 2017 Annual Meeting, and is not sponsored by the USCAP.  The USCAP does not officially endorse any company or its products and does not award CME credits for attendance at Exhibitor Seminars.